Advanced Therapies Manufacturing Strategy Digital 

Assess the current manufacturing landscape in the context of the COVID-19 pandemic. What are the short and long term implications for advanced therapeutics development?

July 14 - 15, 2020 | Virtual Event

Advanced Therapies Manufacturing Strategy Digital | Program

Advanced Therapies Manufacturing Strategy Digital | Program

Join advanced therapies stakeholders for the free virtual Advanced Therapies Manufacturing Strategy Summit, July 14-15, to take stock of the first half of 2020 and the short and long term implications of the ongoing COVID-19 pandemic. Registration is free (vendors and solution providers, please note your registration is not free). . 

Hear an update on FDA regulatory guidance for manufacturers, take part in a virtual Q&A, and gain insight on current consortia initiatives and priorities for cell and gene therapy manufacturing and commercial development. Some industry leaders joining us include: 

  • Peter Marks MD, PhD, Director, Center for Biologics Evaluation and Research (CBER) FDA
  • Michael Lehmicke, Director, Science and Industry Affairs, Alliance for Regenerative Medicine (ARM) 
  • Kelvin H. Lee, Institute DirectorNational Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL)
  • Steven Goodman, Head of Drug Product ManufacturingBluebird Bio
  • Vlad Hogenhuis, Chief Operating Officer (fmr.), Ultragenyx

Fill out the form to download the full event program to see what we have in store for you, and don't forget to secure your registration.

If you are interested in sponsoring or want additional information about the event, email

Registration is free, secure your spot here.

Please note: That all fields marked with an asterisk (*) are required.